Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease
Glucose-lowering interventions in Type 2 diabetes mellitus have demonstrated reductions in microvascular complications and modest reductions in macrovascular complications. However, the degree to which targeting different HbA1c reductions might reduce risk is unclear.Participant-level data for Trial...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Sprog: | English |
| Udgivet: |
Wiley
2017
|